Why choose Varenzin-CA1?
Varenzin-CA1 is the FIRST and ONLY FDA conditionally approved option for the treatment of non-regenerative anemia in cats with CKD, setting the new standard of care for cats suffering the debilitating effects of this often fatal disease.
- A first of its kind in veterinary medicine, Varenzin-CA1 stimulates a cat’s body to create its own erythropoietin (EPO)*
- Reasonable expectation of efficacy with minimal side effects²
- Approved for convenient at-home treatment; no in-clinic injections needed
- No costly and inconvenient extra label use of erythropoietin stimulating agents (ESAs)
*Versus administering with a human EPO product
Varenzin-CA1 Dosing Information
Breakthrough innovation meets at-home convenience
Made just for cats with anemia related to their CKD, Varenzin-CA1 is a flavored, orally administered liquid given once daily that’s convenient and simple to dose.
- Step 1
Shake well before use. Remove screw cap.
- Step 2
Place the enclosed syringe nozzle firmly into the opening of the bottle.
- Step 3
Turn the bottle upside down and withdraw necessary volume. Turn the bottle upright before removing syringe.
- Step 4
Administer directly into the cat's mouth.
Varenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.
IMPORTANT SAFETY INFORMATION:
For oral use in cats only. Keep this drug, including used syringes, out of reach of children. Wash hands immediately after use. In case of accidental ingestion, seek medical advice immediately. Women who are pregnant or may become pregnant should administer the product with caution. Varenzin-CA1 should not be administered to cats that are pregnant, lactating or intended for breeding or to cats with known hypersensitivity to molidustat or to any of the inactive ingredients. Use with caution in cats with a history of seizures and in cats predisposed to thromboembolic disease. Hematocrit (HCT) or packed cell volume (PCV) levels should be monitored regularly as polycythemia may result from use of Varenzin-CA1. Varenzin-CA1 has not been evaluated in cats less than 1 year of age. The most common adverse reactions included vomiting, increases in systolic blood pressure and mild transient increase in serum potassium. View product label.
For the management of weight loss in cats with chronic kidney disease.
IMPORTANT SAFETY INFORMATION:
For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin, or in cats with hypersomatotropism (acromegaly). Elura may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration, or hepatic dysfunction. Elura has not been evaluated in cats younger than 5 months of age, or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy.
Please see Elura label for product safety information.